ArticleBMC genomics2026
Genomic insights into the biosynthetic capacity of the sponge-associated fungus Aspergillus puulaauensis Hmp-F48.
Article in BMC genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMarine-derived fungi are prolific producers of structurally diverse secondary metabolites with significant pharmaceutical potential. The discovery of natural products has been unprecedentedly accelerated by the prediction of biosynthetic gene clusters (BGCs) within the whole-genome context. This study presents the whole-genome sequencing, comprehensive annotation, and biosynthetic potential predictions of the sponge-associated fungus Aspergillus puulaauensis Hmp-F48.
resultsGenome sequencing of A. puulaauensis Hmp-F48 generated a high-quality draft assembly of 35.86 Mb. Structural annotation revealed a complex genomic architecture, comprising 10,611 protein-coding genes, 210 non-coding RNAs, and 155 tRNAs. Functional annotation using NR, Swiss-Prot, GO, KEGG, and eggNOG databases highlighted significant enrichment in biosynthetic, metabolic, and transport processes. AntiSMASH analysis identified 78 putative BGCs, including 16 type I polyketide synthase (T1PKS), 27 nonribosomal peptide synthetase (NRPS), 7 hybrid PKS-NRPS, 9 terpene-related clusters, 6 RiPP-related clusters and 13 clusters associated with other secondary metabolites. Several clusters exhibited high homology to known BGCs responsible for bioactive secondary metabolites, including asperthecin, sterigmatocystin, calbistrins, F-9775 A/B, nidulanin A, aspercryptins, fellutamide B, acetylaranotin, burnettramic acid A, equisetin, and pyranonigrin E. Experimental isolation confirmed the presence of PKS-derived metabolites, including sterigmatocystin, averantin, and decumbenones — one of which represents a previously undescribed congener.
conclusionsThis study highlights the extensive biosynthetic potential of A. puulaauensis Hmp-F48, offering valuable insights into its capacity for secondary metabolite production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.